Surveillance Estimates Prevalence of Neural Tube Defects in Births to Women With HIV
The prevalence of neural tube defects (NTDs) in births to mothers with HIV from 2013 to 2017 was estimated to be 7.0 per 10,000 live births.
HIV/AIDS
Prevelance of Neural Tube Defect in HIV-Exposed Individuals
The prevalence of neural tube defects (NTDs) is 7.0 per 10,000 live births in HIV-exposed pregnancies, which is similar to the prevalence in the general population.
Prevalence of HIV-Associated Distal Sensory Peripheral Neuropathy in Resource-Limited Settings
Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.
Fetal Exposure to Efavirenz May Increase Risk for Microcephaly
In utero exposure to efavirenz is associated with an increased risk for microcephaly among children who are HIV-exposed but uninfected.
Updated Labeling for Efavirenz-Containing Products Warns of Possible Late-Onset Neurotoxicity
The Warnings and Precautions section has been updated to address the potential for late-onset neurotoxicity, including ataxia and encephalopathy with efavirenz treatment.
An Overview of HIV-Associated Neurocognitive Disorder
Rates of HIV-associated dementia have decreased from approximately 50% in the pre-cART era to 2% currently. However, roughly 50% of patients treated with cART have the milder forms of HIV-associated neurocognitive disorder (HAND).
Neurologic Impairment May Persist in HIV Encephalopathy Despite Potent ART
Despite potent antiretroviral therapy, HIV-associated dementia results in significant morbidity and mortality.
Neural-Tube Defects Increased for Offspring of Women on Dolutegravir
For HIV-infected women receiving dolutegravir from the time of conception, 0.3 percent have offspring with neural-tube defects, representing a small but significant increase compared with other ART exposures.
HIV Infection Increases Risk for Cardiovascular Disease and Stroke
Findings reinforce the importance of primary prevention of cardiovascular disease in people living with HIV.
Aging-Related Brain Changes No Different in HIV Positive, Negative
HIV-positive patients with virological suppression did not have different rates of aging-relating cognitive decline compared with HIV-negative patients.
Next post in General Neurology
